University of Michigan
PhD, 2015, Pharmacology

University of California, Santa Cruz
MS, 2009, Chemistry

University of California, Santa Cruz
BS, 2007, Chemistry

C. Gianna Hoffman-Luca, PhD

Patent Agent

t 617-248-5292   f 617-248-4000

Gianna Hoffman-Luca, PhD, utilizes her professional and technical experience in providing patent protection to various establishments within the life sciences industry.  Her in-depth understanding of pharmacology, biology and chemistry allows her to deliver optimal support and solutions to an array of clients.

Practice Focus

Intellectual Property: assists in the preparation and prosecution of patent applications, freedom-to-operate analysis, due diligence reviews, infringement opinions and executes technical scientific analysis for litigation matters.

Intellectual Property Litigation:  advises litigation teams on technical aspects. Assists patent prosecution and litigation teams in AIA post grant review proceedings, including inter partes review.

Previous Experience

Dr. Hoffman-Luca obtained her PhD in Pharmacology from the University of Michigan, where her research focused on identifying mechanisms of resistance to small molecule targeted anticancer therapies.  She investigated the mechanisms of action of apoptosis inducing cancer drugs and novel combination strategies to increase patient survival.

Prior to her PhD, Dr. Hoffman-Luca completed her Master’s degree in Chemistry at the University of California Santa Cruz, where she worked on the synthesis and characterization of inorganic nitrosyls for potential use as photodynamic therapy agents.  She also worked as a legal intern at Genzyme assisting in patent prosecution and litigation matters.

Representative Engagements

  • Preparation and global prosecution of patent applications directed to biologics, chemical and pharmaceutical products and related methods of preparation and use.
  • Assists in the management of patent portfolios pharmaceutical, biotech and academic clients.
  • Conducts due diligence, freedom-to-operate analysis and participates on patent litigation teams.

Publications and Presentations

  • “Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia in Vitro and in Vivo,” first author, Clinical Cancer Research, June 2015.
  • “Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment,” first author, PLoS One, June 2015.
  • “SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression,” co-author, Cancer Research, Oct 2014.
  • “Understanding and overcoming resistance of MDM2 and Bcl-2/Bcl-xL small-molecule inhibitors in human cancer,” speaker, ACS Spring National Meeting, New Orleans, April 2013.
  • “Syntheses, structures, and photochemistry of manganese nitrosyls derived from designed Schiff base ligands: potential NO donors that can be activated by near-infrared light,” first author, Inorganic Chemistry, Oct 2009.
  • “Formation of a triply bridged mu-oxo diiron(III) core stabilized by two deprotonated carboxamide groups upon photorelease of NO from a [Fe-NO]6 iron nitrosyl,” co-author, Dalton Transactions, Dec 2007.

Professional and Community Involvement

Dr. Hoffman-Luca is a member of the American Chemical Society and the American Association for Cancer Research.


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.